Our professionals
Dr. Juan Dubrot Armendáriz
Principal investigator of the Tumor Evasion and New Targets group.
Preferential dedication to the study of resistance mechanisms to therapy in cancer, discovery of new therapeutic targets and strategies through functional genomics and development of radiotherapy and AAV-based gene therapy.
Professional career
- Degree in Biology from the University of Navarra in 2005.
- Ph.D. in Biology from the University of Navarra in 2009.
- Postdoctoral training at University of Geneva (Switzerland).
- Group leader at Broad Institute of MIT and Harvard (Cambridge, US).
- PI in Solid Tumors Program at Cima University of Navarra since 2022.
RESEARCH AREAS
He is currently the principal investigator of the Tumor Evasion and Novel Targets group, focused on understanding the mechanisms by which tumors are able to resist and evade current treatments. Specifically, he seeks to identify the mechanisms of resistance that limit the antitumor effects of therapies such as radiotherapy or immunotherapy based on checkpoint inhibitors such as PD-1 or CTLA-4.
In this way, new therapies and combinations can be identified to improve the survival and quality of life of patients.
AREAS OF INTEREST
I study cancer immunology using a multi-omic approach. My major contributions have been in cancer immunotherapy, searching for novel therapeutic strategies and the understanding of molecular and cellular mechanisms of resistance that promote tumor progression.
Along with scientific production, I take training and mentoring of young scientists very seriously and is a main focus during their stay in my lab. The purpose of my research is to make a big impact in cancer patients and their families while fostering the development of future scientific leaders.
Activity
As an educator
- Director of thesis (3) and master (2) projects at the University of Navarra.
As a researcher
- Co-author of more than 50 scientific articles with more than 2500 citations.
- Publications in Nature, Nature Immunology, Cancer Discovery, Immunity, Nature Communications, Journal of Experimental Medicine…
- PI in several projects funded by public and private entities.
- Author of 3 patents.
More information
Latest scientific publications
- Protocol for in vivo CRISPR screening using selective CRISPR antigen removal lentiviral vectors. Scientific Publication Feb 1, 2023 | Magazine: STAR Protocols
- In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Scientific Publication Oct 23, 2022 | Magazine: Nature Immunology